Capstone Therapeutics (NASDAQ:CAPS) Posts Quarterly Earnings Results, Misses Expectations By $0.21 EPS

Capstone Therapeutics (NASDAQ:CAPS) issued its quarterly earnings results on Wednesday. The company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of $0.12 by ($0.21), FiscalAI reports. The firm had revenue of $21.48 million during the quarter, compared to analysts’ expectations of $20.39 million. Capstone Therapeutics had a negative return on equity of 114.15% and a negative net margin of 41.26%.

Capstone Therapeutics Stock Down 30.3%

NASDAQ:CAPS traded down $0.10 on Wednesday, reaching $0.22. 9,057,381 shares of the stock traded hands, compared to its average volume of 1,896,040. The company has a current ratio of 0.95, a quick ratio of 0.29 and a debt-to-equity ratio of 0.79. The company has a market capitalization of $3.36 million, a price-to-earnings ratio of -0.07 and a beta of -1.52. Capstone Therapeutics has a 12 month low of $0.21 and a 12 month high of $2.07. The company’s fifty day simple moving average is $0.27 and its 200 day simple moving average is $0.44.

Wall Street Analyst Weigh In

Separately, Weiss Ratings raised Capstone Therapeutics from a “sell (e)” rating to a “sell (e+)” rating in a research report on Thursday, August 6th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, Capstone Therapeutics presently has an average rating of “Sell”.

Institutional Investors Weigh In On Capstone Therapeutics

A hedge fund recently bought a new position in Capstone Therapeutics stock. DRW Securities LLC acquired a new position in Capstone Therapeutics Corp. (NASDAQ:CAPS) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 125,422 shares of the company’s stock, valued at approximately $91,000. DRW Securities LLC owned about 1.51% of Capstone Therapeutics as of its most recent SEC filing. 2.55% of the stock is currently owned by institutional investors and hedge funds.

About Capstone Therapeutics

Capstone Therapeutics Corp., a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism. The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010. Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona.